Investors



Overview

60P was founded with a mission to discover, develop and distribute new medicines for treatment, and prevention of tropical diseases. Our core business is delivering tropical disease drug research and development while providing an attractive return for investors.


We have created an open innovation approach to reduce the time, cost, and risk needed to build a portfolio of drug discovery and development projects. We collaborate with leading research institutions in the United States, Australia, and Singapore to discover and develop medications for dengue fever and malaria prevention.

Operations

HQ: Washington, D.C. (USA)

R&D: Australia & Singapore


Core Team

Geoffrey Dow, PhD, MBA
CEO

Ty Miller, CPA 
CFO/Director

Doug Loock
, MBA
VP Commercial Operations

Jennifer Herz
Director 

Bryan Smith, MD
CMO

Key Collaboration Partners

U.S. Army

Duke-NUS Medical School

Singapore General Hospital

Monash University


Strategic Partners

U.S. Army

Clinical Network Services

Biointelect/Biocelect

History
  • 2010: 60 Degrees Pharmaceuticals (60P) established
  • 2012: Secured $2 million in initial funding
  • 2013: Established an Australian subsidiary to support global research projects
  • 2014: Commercialization of tafenoquine for malaria prophylaxis initiated with U.S. Army
  • 2015: The Singapore Ministry of Health (MOH) provides regulatory approval and $4 million in financial support to conduct a phase II dengue study
  • 2016: Knight Pharmaceuticals provides $4 million in financing to support the 60P tafenoquine program
  • 2017: 60P files IND for tafenoquine with a target indication for the prevention of malaria






About  |  Tropical Diseases  |  Products  |  Research  |  Responsibility  |  Investors  |  Media  |  Careers  |  Contact 

 1025 Connecticut Avenue NW, Suite 1000   Washington DC 20036 
Phone: 1-240-351-1167   Email: inquiries@60degreespharma.com 

 Content © 2017. 60° Pharmaceuticals, LLC. All rights reserved.